Lauren Sharan Ranard

Lauren Sharan Ranard

Auto-generated profile, based on publicly available information

Lauren Sharan Ranard

Structural Heart and Valve Center, NewYork-Presbyterian Hospital, Columbia University Irving Medical Center, New York, New York, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
AGAakriti Gupta
Aakriti Gupta
MMMahesh V. Madhavan
Mahesh V. Madhavan
TPTimothy J. Poterucha
Timothy J. Poterucha
EDErsilia M. DeFilippis
Ersilia M. DeFilippis
JHJessica A. Hennessey
Jessica A. Hennessey
SPSahil A. Parikh
Sahil A. Parikh
The coronavirus disease 2019 (COVID-19) can result in a hyperinflammatory state, leading to acute respiratory distress syndrome (ARDS), myocardial injury, and thrombotic complications, among other sequelae. Statins, which are known to have anti-inflammatory and antithrombotic properties, have been studied in the setting of other viral infections, but their benefit has not been assessed in COVID-19. This is a retrospective analysis of patients admitted with COVID-19 from February 1st through May 12th, 2020 with study period ending on June 11th, 2020. Antecedent statin use was assessed using medication information available in the electronic medical record. We constructed a multivariable logistic regression model to predict the propensity of receiving statins, adjusting for baseline sociodemographic and clinical characteristics, and outpatient medications. The primary endpoint includes in-hospital mortality within 30 days. A total of 2626 patients were admitted during the study period, of whom 951 (36.2%) were antecedent statin users. Among 1296 patients (648 statin users, 648 non-statin users) identified with 1:1 propensity-score matching, statin use is significantly associated with lower odds of the primary endpoint in the propensity-matched cohort (OR 0.47, 95% CI 0.36–0.62, p < 0.001). We conclude that antecedent statin use in patients hospitalized with COVID-19 is associated with lower inpatient mortality.

1 October 2021 in Journal of Cardiac Failure
Verified
Journal Article
Open access
SKSanjog Kalra
Sanjog Kalra
LRLauren S. Ranard
Lauren S. Ranard
SMSehrish Memon
Sehrish Memon
PRPrashant Rao
Prashant Rao
AGA. Reshad Garan
A. Reshad Garan
DBDaniel Burkhoff
Daniel Burkhoff
Cardiogenic shock (CS) is a condition associated with high mortality rates in which prognostication is uncertain for a variety of reasons, including its myriad causes, its rapidly evolving clinical course and the plethora of established and emerging therapies for the condition. A number of validated risk scores are available for CS prognostication; however, many of these are tedious to use, are designed for application in a variety of populations and fail to incorporate contemporary hemodynamic parameters and contemporary mechanical circulatory support interventions that can affect outcomes. It is important to separate patients with CS who may recover with conservative pharmacological therapies from those in who may require advanced therapies to survive; it is equally important to identify quickly those who will succumb despite any therapy. An ideal risk-prediction model would balance incorporation of key hemodynamic parameters while still allowing dynamic use in multiple scenarios, from aiding with early decision making to device weaning. Herein, we discuss currently available CS risk scores, perform a detailed analysis of the variables in each of these scores that are most predictive of CS outcomes and explore a framework for the development of novel risk scores that consider emerging therapies and paradigms for this challenging clinical entity.

9 June 2020 in Circulation
Verified
Journal Article
Closed access
PDF file
EDErsilia M. DeFilippis
Ersilia M. DeFilippis
LRLauren S. Ranard
Lauren S. Ranard
DBDavid D. Berg
David D. Berg

6 November 2023 in JACC
Verified
Journal Article
Closed access
LRLauren S. Ranard
Lauren S. Ranard
RBRobert O. Bonow
Robert O. Bonow
RNRick Nishimura
Rick Nishimura
MMMichael J. Mack
Michael J. Mack
VTVinod H. Thourani
Vinod H. Thourani
VRVera H. Rigolin
Vera H. Rigolin

5 March 2026 in Science
Verified
Journal Article
Open access
KZKaiyue Zhang
Kaiyue Zhang
HTHongyan Tao
Hongyan Tao
DZDASHUAI ZHU
DASHUAI ZHU
ZYZhang Yue
Zhang Yue
SHShiqi Hu
Shiqi Hu
KCKe Cheng
Ke Cheng
Self-amplifying RNA (saRNA) enables sustained protein expression from a single administration. In this study, we developed an intramuscular saRNA-lipid nanoparticle (saNppa-LNP) therapy encoding natriuretic peptide type A ( Nppa ) for cardioprotection. A single injection induced sustained pro–atrial natriuretic peptide (pro-ANP) secretion for 4 weeks; pro-ANP was subsequently cleaved by the cardiac protease corin into active ANP, producing robust cardioprotection in mouse and swine myocardial infarction models. At equivalent doses, saNppa achieved greater efficacy than conventional mRNA. Single-nucleus transcriptomics identified natriuretic peptide receptor 1–positive ( Npr1 + ) endothelial and epicardial cells as primary effectors, with saNppa-LNPs reshaping their paracrine profile to promote cardiomyocyte regeneration and suppress fibrosis. Longitudinal biosafety assessments revealed no systemic toxicity. Together, these results demonstrate that one-shot saNppa-LNP therapy offers durable cardioprotection, supporting the broader potential of saRNA-LNP–based approaches for cardiac therapy.

31 October 2022 in Structural Heart
Verified
Journal Article
Open access
LRLauren S. Ranard
Lauren S. Ranard
KGKenneth Guber
Kenneth Guber
JFJustin Fried
Justin Fried
KTKoji Takeda
Koji Takeda
YKYuji Kaku
Yuji Kaku
AMAmirali Masoumi
Amirali Masoumi
Background: There are numerous risk-prediction models applied to acute myocardial infarction-related cardio-genic shock (AMI-CS) patients to determine a more accurate prognosis and to assist in patient triage. There is wide heterogeneity among the risk models including the nature of predictors evaluated and their specific outcome measures. The aim of this analysis was to evaluate the performance of 20 risk-prediction models in AMI-CS patients. Methods: Patients included in our analysis were admitted to a tertiary care cardiac intensive care unit with AMI-CS. Twenty risk-prediction models were computed utilizing vitals assessments, laboratory investigations, hemo-dynamic markers, and vasopressor, inotropic and mechanical circulatory support available from within the first 24 hours of presentation. Receiver operating characteristic curves were used to assess the prediction of 30-day mortality. Calibration was assessed with a Hosmer-Lemeshow test. Results: Seventy patients (median age 63 years, 67% male) were admitted between 2017 and 2021. The models' area under the curve (AUC) ranged from 0.49 to 0.79, with the Simplified Acute Physiology Score II score having the most optimal discrimination of 30-day mortality (AUC: 0.79, 95% confidence interval [CI]: 0.67-0.90), fol-lowed by the Acute Physiology and Chronic Health Evaluation-III score (AUC: 0.72, 95% CI: 0.59-0.84) and the Acute Physiology and Chronic Health Evaluation-II score (AUC: 0.67, 95% CI: 0.55-0.80). All 20 risk scores demonstrated adequate calibration (p > 0.05 for all). Conclusions: Among the models tested in a data set of patients admitted with AMI-CS, the Simplified Acute Physiology Score II risk score model demonstrated the highest prognostic accuracy. Further investigations are required to improve the discriminative capabilities of these models or to establish new, more streamlined and accurate methods for mortality prognostication in AMI-CS.